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Abstract: The dermaseptin peptides, mainly derived from the skin secretions of Hylidae frogs,
belong to a superfamily of antimicrobial peptides and exhibit diverse antimicrobial and anticancer
activities with low cytotoxicity. Here, we reported a novel dermaseptin peptide, from the South
American orange-legged leaf frogs, Pithecopus (Phyllomedusa) hypochondrialis, processing the shortest
peptide length, namely Dermaseptin-PH. The complementary DNA (cDNA) encoding biosynthetic
precursor of Dermaseptin-PH was initially identified by the rapid amplification of cDNA ends
PCR (RACE-PCR) technique from the skin secretion. The predicted primary structure was
confirmed by a combination of reverse-phase high performance liquid chromatography (RP-HPLC)
and MS/MS fragmentation from the skin secretion. Chemically-synthetic Dermaseptin-PH was
investigated using a range of bioactivity assessment assays to evaluate the biological activities
and cytotoxicity of Dermaseptin-PH. Dermaseptin-PH inhibited the growth of Gram-negative
bacteria, Gram-positive bacteria, and pathogenic yeast Candida albicans. In addition, Dermaseptin-PH
showed a broad-spectrum of anticancer activities against several cancer cell lines including MCF-7,
H157, U251MG, MDA-MB-435S, and PC-3. The potent antimicrobial and anticancer activities of
Dermaseptin-PH make it a promising candidate in the discovery of new drugs for clinical applications,
and the relatively short sequence of Dermaseptin-PH can provide new insight for the research and
structural modification of new peptide drugs.
Keywords: dermaseptin; amphibian skin secretion; molecular cloning; antimicrobial; anticancer
1. Introduction
Antimicrobial peptides (AMPs), as multifunctional host-defence peptides, have clear antibacterial
functions against a series of bacteria, fungi, viruses, and parasites, and have gained widespread
interest in recent years [1]. AMPs not only exist in the secretions of frogs and toads, but are also
present in microorganisms, plants, animals, and even human bodies. In mammals, these short
cationic peptides which are also called host-defence peptides (HDPs) act as natural antibiotics and
participate in the immunoregulation or killing of pathogenic microorganisms after invasion [2,3].
Nevertheless, scientists found that HDPs are more inclined to induce the immune response mechanisms
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under physiological conditions to protect hosts from infection of pathogens, than to be directly involved
in killing bacteria [4,5].
With the ever-increasing problems of antibiotic resistance and the emergence of superbacteria,
the current clinical antibiotics cannot meet the demand of patients [6,7]. The various mechanisms of
multidrug resistance limit the development of antibiotics. Some pathogens, including Enterococcus faecium,
MRSA, and Pseudomonas aeruginosa, are drug resistant or multidrug resistant bacteria that threaten
the life of immunocompromised sufferers. The ESKAPE pathogens which are comprised of six
multi-drug resistant microbes are generally recommended for screening of antimicrobial drugs [8].
However, unlike the general mechanisms of most antibiotics targeting the particular enzymes in the
process of pathogenic metabolism, AMPs display totally different antimicrobial mechanisms which
make them one of the most promising anti-infective drug candidates that meet the customers’ need [9].
Besides, antimicrobial peptides with anticancer activities have been widely reported in some
literatures, and apparently, as a result, are attracting scientists to investigate and discover new
anticancer candidates. Although the development of anticancer peptides in clinical therapy is beset by
difficulties, there are still a few AMPs undergoing clinical trials. LL-37 is a human source cathelicidin
peptide which exists in human respiratory and reproductive system and skin [10]. A collaboration
programme between the National Cancer Institute and the M.D. Anderson Cancer Centre, indicated
that LL-37 was an efficient antitumour agent against melanoma, and was undergoing Phase II clinical
trials at present [11]. Another candidate anticancer drug, LTX-315, an engineered lytic peptide,
is currently in Phase I clinical trial for treatment against transdermally accessible tumours. It is
worth noting that anticancer peptides can enhance therapeutic effects through combination with other
therapeutic approaches, including surgery, chemotherapy, radiotherapy, and even immunotherapy.
The combination of LTX-315 with immunotherapy for treatment of patients with transdermally
accessible tumours is in the process of trials, which provide possibilities from more therapeutic
aspects [12–14].
The overall objectives of this study were to isolate and identify a novel antimicrobial peptide,
named Dermaseptin-PH, from the skin secretion of the South American orange-legged leaf frog,
Pithecopus (Phyllomedusa) hypochondrialis [15], to measure the bioactivities of it and to assess its
therapeutic potential. To this end, the complementary DNA (cDNA) encoding Dermaseptin-PH
biosynthetic precursor was cloned by “shotgun” molecular cloning and subsequently, the predicted
mature peptide was identified by reverse-phase high performance liquid chromatography (RP-HPLC)
from the crude skin secretion and the primary structure was confirmed by MS/MS sequencing
technique. After chemical synthesis of Dermaseptin-PH, antimicrobial activity was investigated using
several Gram-negative and Gram-positive bacteria, and a pathogenic yeast included. In the meanwhile,
anticancer activity was assessed on a wide range of cancer cell lines in vitro. The cytotoxicity of
Dermaseptin-PH against eukaryotic cells was evaluated on horse red blood cells and human dermal
microvascular endothelium cells.
2. Results
2.1. “Shotgun” Cloning of Dermaseptin-PH Precursor-Encoding cDNA from a Skin Secretion-Derived cDNA
Library of Pithecopus hypochondrialis and Bioinformatic Analysis
A full-length cDNA encoding one novel dermaseptin peptide named Dermaseptin-PH was
identified from the cDNA library constructed by isolating mRNA from the skin secretion of
Pithecopus hypochondrialis. The biosynthetic precursor of Dermaseptin-PH consisted of a hydrophobic
signal peptide region followed by an acidic spacer and a single copy of the predicted mature peptide
(Figure 1). The translated open-reading frame of this novel dermaseptin biosynthetic precursor
consisted of 312 base pairs encode 70 amino acids. The prepropeptide comprises a 22-amino acid
signal peptide region followed by three Glu residues, and a typical processing site Lys–Arg amino
acid pairing. Following the remaining acidic spacer domain, another processing site Lys–Arg is
showed before the mature Dermaseptin-PH, that contains 23 amino acid residues followed by an
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amidation consensus motif –Gly–Gly–Gln [16]. The nucleotide sequence of Dermaseptin-PH has been
deposited in the GenBank Database (https://www.ncbi.nlm.nih.gov/genbank/) under the accession
code MF805718.
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Additionally, the alignments of the full length prepropeptides of Dermaseptin-PH with 
Dermaseptin-1, Dermaseptin-H1, and Dermaseptin-H2 were displayed below (Figure 2). The 
sequences showed a highly conserved signal peptide domain consisting of 22 amino acid residues 
and the acidic spacer region comprising 20–21 residues. Besides, they have a –GGQ or –GEQ 
extension at C-terminal. The mature peptide amino acid sequences derived from the same species 
were aligned in Figure 3. An identical Trp residue in the position three at N-terminal and a consensus 
motif of –AA/GKAA– amphipathic structure in the middle region was observed. 
 
Figure 2. Alignments of the amino acid sequences of the prepropeptides of Dermaseptin-1, 
Dermaseptin-H1, Dermaseptin-H2, and Dermaseptin-PH comprise five domains, 1: putative  
N-terminal signal peptide region; 2: acidic amino acid rich spacer peptide region; 3: endoproteolytic 
cleavage point; 4: mature peptide progenitor region; 5: extension of biosynthetic precursor. Amino 
acid indicated with bold type serves as an amide donor for C-terminal amidation. The identical amino 
acid residues are indicated by the asterisks. 
Figure 1. Nucleotide and translated open-reading frame amino acid sequences of Dermaseptin-PH
from the skin secretion of Pithecopus hypochondrialis. The putative signal peptide is double-underlined,
the mature peptide is single-underlined, and the stop codon is marked by an asterisk.
Additionally, the alignments of the full length prepropeptides of Dermaseptin-PH with
Dermaseptin-1, Dermaseptin-H1, and Dermaseptin-H2 were displayed below (Figure 2). The sequences
showed a highly conserved signal peptide domain consisting of 22 amino acid residues and the acidic
spacer region comprising 20–21 residues. Besides, they have a –GGQ or –GEQ extension at C-terminal.
The mature peptide amino acid sequences derived from the same species were aligned in Figure 3.
An identical Trp residue in the position three at N-terminal and a consensus motif of –AA/GKAA–
amphipathic structure in the middle region was observed.
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mass spectrometer (MALDI-TOF-MS), and the fraction with a mass coincident with that of the 
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Figure 3. Alignments of amino acid sequences of Dermaseptin-1 (Accession No. P84596),
Dermaseptin-2 (Accession No. P84597), Dermaseptin-3 (Accession No. P84598), Dermaseptin-4
(Accession No. P84599), Dermaseptin-5 (Accession No. P84600), Dermaseptin-6 (Accession No. P84601),
Dermaseptin-7 (Accession No. P84880), Dermaseptin-H1 (Accession No. Q0VZ36), Dermaseptin-H2
(Accession No. Q0VZ37) and Dermaseptin-PH derived from the f og Pithecopus hypochondrialis are
displa ed. The dentical mino ac s are shaded in black; the amino acid w th sl ght changes are
indicated in bold type; the gaps are used to maximise alignments.
2.2. Identification and Structural Characterization of Dermaseptin-PH in Skin Secretion of
Pithecopus hypochondrialis
The fractions from the lyophilised crude skin secretion of Pithecopus hypochondrialis were eluted
by RP-HPLC and fractions containing different natural components were collected every minute
(Figure 4). Each fraction was analysed by matrix-assisted laser desorption ionization time-of-flight
mass spectrometer (MALDI-TOF-MS), and the fraction with a mass coincide t with that of the pre icted
mature p ptide identified by the genomic study is indicat d by an arrow. The amino acid sequence
of mature peptide, Dermaseptin-PH, was further confirmed by MS/MS fragmentation sequencing
(Figure 5). The amidated C-terminal post-translational modification with the Gly residue following the
C-terminal amino acid residue of the mature peptide domain was also verified in the sequencing result.
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2.4. Antimicrobial Activity and Haemolytic Activity of Dermaseptin-PH 
Dermaseptin-PH was demonstrated to have a broad-spectrum of antimicrobial activity against 
the Gram-negative bacterium, Escherichia coli; the Gram-positive bacterium, Staphylococcus aureus; 
and the pathogenic yeast, Candida albicans, with minimum inhibitory concentration (MIC) results 
i r 5. /MS fragme tation datasets derived from ions coincid nt with the mass of
Dermaseptin-PH. Predicted singly nd doubly charged b-ions and y-ions arising from MS/MS
fragmentation of Dermaseptin-PH. Ions detected by MS/MS fragme tation are indicated in red
and blue.
2.3. Circular Dichroism Spectroscopy
The secondary structure of Dermaseptin-PH was successfully examined by circular dichroism
spectroscopy in both aqueous and membrane-mimic environment (Figure 6). Dermaseptin-PH showed
a random coil conformation in ammonium cetate/water solution, wh le it exhibited typical α-helical
struc ure in 50% 2,2,2-trifluoroeth nol (TFE)/10 mM ammonium acetat /water solution. The helicity
of Dermaseptin-PH was calculated as 35% by DichroWeb webserver [17].
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the ra -negative bacteriu , Escherichia coli; the ra -positive bacteriu , Staphylococcus aureus;
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and the pathogenic yeast, Candida albicans, with minimum inhibitory concentration (MIC) results
ranging from 16 to 32 µM and minimum bactericidal concentration (MBC) results ranging from 16 to
64 µM (Table 1). The antimicrobial activity of Dermaseptin-PH against the tested microorganisms
was showed in Figure 7. Dermaseptin-PH showed more effective potency to E. coli and C. albicans
at the concentration of 16 µM, than to S. aureus with 32 µM. It is also important to note that
Dermaseptin-PH exhibited more effective antimicrobial activity against E. coli (16 µM) than ampicillin
(Amp) (36.6 µM). However, Dermaseptin-PH displayed lower efficiency than norfloxacin (Nor) on
both MIC and MBC results against the six tested microorganisms. In addition, it is worthy of note that
Dermaseptin-PH showed low cytotoxicity to mammalian red blood cells at its effective concentration
against microorganisms in a range of concentrations from 16 to 64 µM (Figure 8).
Table 1. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
of Dermaseptin-PH, ampicillin (Amp) and norfloxacin (Nor) against tested microbes.
Strains
MIC (µM) MBC (µM)
Dermaseptin-PH Amp Nor Dermaseptin-PH Amp Nor
Escherichia coli 16 36.6 0.6 16 36.6 0.6
Pseudomonas aeruginosa 64 - 2.5 >512 - 5.2
Staphylococcus aureus 32 0.3 1.3 64 0.3 2.5
MRSA >512 - 2.5 >512 - 5.2
Enterococcus faecalis 32 4.8 5.2 64 4.8 5.2
Candida albicans 16 - 1.3 32 - 2.5
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Figure 8. The haemolytic activity of Dermaseptin-PH was tested on horse red blood cells. The positive
control group was treated with 1% Triton X-100 lysis buffer.
2.5. Anti-Biofilm Activity of Dermaseptin-PH
Dermaseptin-PH exhibited moderate antibiofilm activities against both E. coli and S. aureus
(Figure 9). It processed the same potency on the inhibition of biofilm of both strains, but showed 2-fold
more effective activity w n eradicating 90% matur b ofilm of S. aureus (Table 2).
Table 2. The antibiofilm activity of Dermaseptin-PH against E. coli and S. aureus.
Strains MBIC50 (µM) I 90 (µ ) MBEC50 (µM) MBEC90 (µM)
E. coli 32 64 64 256
S. aureus 32 64 128
MBI , i i biofilm inhibitory concentra ion; MBEC, mini um biofilm eradication oncentration; MBIC50,
minimum biofilm inhibitory concentration required to inhibit the formation of 50% of biofilm; MBIC90, minimum
biofilm inhibitory concentration required to inhibit the formation of 90% of biofilm; MBEC50, minimum biofilm
eradication concentration required to eradicate 50% of the formed biofilm; MBEC90, minimum biofilm eradication
concentratio required to eradic te 90% of the formed biofilm.
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of Dermaseptin-PH on P. aeruginosa and E. faecalis were two times and four times higher, at 16 and  
32 μM, respectively. At the MICs against the respective microorganisms, the permeability rate of 
Dermaseptin-PH on E. coli, P. aeruginosa, S. aureus, E. faecalis, and C. albicans was 46.4%, 131.5%, 
103.6%, 44.3%, and 22.9%. And, the permeability rate of Dermaseptin-PH on E. coli, S. aureus,  
E. faecalis, and C. albicans was 46.4%, 110.8%, 47.8%, and 37.4% at the respective MBCs. Each assay 
was carried out over at least three individual experiments, with 5 replicates in each. 
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10−9 to 10−4 M (Figure 11). The most obvious proliferation inhibitions observed were on the human 
cancer cell lines MCF-7 with IC50 value of 0.69 μM. Besides, Dermaseptin-PH showed similar 
inhibitory activities against H157, U251MG, and MDA-MB-435S cell lines, with IC50 values of 2.01, 
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dermal microvascular endothelium cells, HMEC-1, with an IC50 value of 4.85 μM. 
Figure 9. The biofilm formation nhibitory activity of Dermaseptin-PH aga nst (a) E. coli and
(b) S. aureus, and the biofilm eradication activity of Dermaseptin-PH against (c) E. coli and (d) S. aureus.
Negative control was btai ed followi g incubation with relevant culture m diu . Data represent
means ± SEM of 5 replicates.
2.6. Bacteria Cell Membrane Permeabilisation Activities of Dermaseptin-PH
The cell membrane permeability of Dermaseptin-PH was tested in a range of concentrations from
8 µM to 128 µM (Figure 10). Dermaseptin-PH showed more effective permeable activity on E. coli,
S. aureus, MRSA, and C. albicans at concentration of 8 µM. The efficient permeabilisation concentrations
of Dermaseptin-PH on P. aeruginosa and E. faecalis were two times and four times higher, at 16 and
32 µM, respectively. At the MICs against the respective microorganisms, the permeability rate of
Dermaseptin-PH on E. coli, P. aeruginosa, S. aureus, E. faecalis, and C. albicans was 46.4%, 131.5%, 103.6%,
44.3%, and 22.9%. And, the permeability rate of Dermaseptin-PH on E. coli, S. aureus, E. faecalis,
and C. albicans was 46.4%, 110.8%, 47.8%, and 37.4% at the respective MBCs. Each assay was carried
out over at least three individual experiments, with 5 replicates in each.
2.7. Cell Proliferation Assay of Dermaseptin-PH
Synthetic peptide Dermaseptin-PH exhibited a broad-spectrum ntiproliferative activity against
MCF-7, H157, U251MG, MDA-MB-435S, and PC-3 human cell lines in a range of concentrations
from 10−9 to 10−4 ( igure 11). The most obvious proliferation inhibitions observed were on the
human cancer cell lines MCF-7 with IC50 value of 0.69 µ . Besides, Dermaseptin-PH showed similar
inhibitory activities against H157, U251MG, and MDA-MB-435S cell lines, with IC50 values of 2.01,
2.36, and 9.94 µM, respectively, and weak anticancer activity against PC-3 cell lines, with an IC50 value
of 11.8 µM. In addition, it is worth noting that Dermaseptin-PH showed slight cytotoxicity on human
dermal microvascular endothelium cells, HMEC-1, with an IC50 value of 4.85 µM.
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following incubation with 5% tryptic soy broth (TSB) in 0.85% NaCl solution. Data represent  
means ± SEM of 5 replicates. The levels of significance are: * p < 0.05, *** p < 0.001. 
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H157; (c) U251MG; (d) MDA-MB-435S; and (e) PC-3 and (f) human dermal microvascular 
endothelium cell HMEC-1; after treatment with Dermaseptin-PH for 24 h at a range of concentrations 
from 10−9 to 10−4 M. The levels of significance are: * p < 0.05, *** p < 0.001. The negative control group 
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2.8. Cancer Cell Membrane Permeabilisation Activities of Dermaseptin-PH 
The cell membrane permeability of Dermaseptin-PH was tested in a range of concentrations after 
incubation with MCF-7 cells for 75 min (Figure 12). The fluorescence detected at initial stage 
Figure 11. The effects of Dermaseptin-PH on proliferation of human cancer cell lines (a) MCF-7;
(b) H157; (c) U251MG; (d) MDA-MB-435S; and (e) PC-3 and (f) human dermal microvascular
endothelium cell HMEC-1; after treatment with Dermaseptin-PH for 24 h at a range of concentrations
from 10−9 to 10−4 M. The levels of significance are: * p < 0.05, *** p < 0.001. The negative control group
was treated with relevant serum-free culture medium.
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2.8. Cancer Cell Membrane Permeabilisation Activities of Dermaseptin-PH
The cell membrane permeability of Dermaseptin-PH was tested in a range of concentrations
after incubation with MCF-7 cells for 75 min (Figure 12). The fluorescence detected at initial stage
demonstrated an immediate damage on cancer cell membrane the moment that Dermaseptin-PH was
added. Each assay was carried out over at least three individual experiments, with 5 replicates in each.
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Figure 12. Cell membrane permeability effects of Dermaseptin-PH on MCF-7 cell by using SYTOX
Green (1 µM) (Life technologies) at peptide concentrations from 1 to 100 µM. Positive control was
obtained following incubation with 0.5% Triton X-100. Negative control was obtained following
incubation with relevant serum-free culture medium. Data represent means ± SEM of 5 replicates.
3. Discussion
Dermaseptins, which belong to an important antimicrobial peptide family, have a wide spectrum
of antimicrobial activity against various microorganisms, including bacteria, fungi, enveloped viruses,
protozoa, and mollicutes [18]. The first dermaseptin peptide named Dermaseptin S1 was discovered
by Mor from frog, Phyllomedusa sauvagii [19]. This novel 34 amino acid residue peptide displayed
lethal activity against pathogenic microorganisms, including filamentous fungi, which is the main
reason for opportunistic infections of i munocompromised patients. In this study, we isolated a
novel dermaseptin peptide, namely Dermaseptin-PH, from the skin secretion of the South American
orange-legged leaf frog, Pithecopus hypochondrialis. Compared to the alignments of the amino acid
sequences of the preprodermaseptins, Dermaseptin-PH shows similar structural characteristics to
other embers with a conserved signal peptide region, which constitutes 22 amino acids as canonical
architecture. However, the variations of signal peptide region of dermaseptin peptide from same
species were observed [20–22], hich might be explained by the mutation occurring due to the different
distribution of specimen. Additionally, the canonical structure in the ature peptide comprises
an identical Trp residue in position three and a conserved – ( /G)KAAL(G/N)A– amphipathic
domain. Besides, the C-terminal amide could influence the activities of AMPs because of 1+ net
positive charge of amide group, and resistance to natural degradation [23]. Moreover, a Val–Gly amino
acid pairing exists in the middle region of Dermaseptin B2, which can divide the amphipathic helix into
N-terminal domain and C-terminal domain, and this may pro ote the penetration into the membrane
of bacteria [24]. However, the Val–Gly amino acid pairing is absent in Dermaseptin-PH, which may
decrease the antimicrobial activity.
AMPs derived fro amphibian skins, as the initial defence protecting themselves from
invasion of pathogens, have a potent and broad-spectrum antimicrobial activity. These low
molecular weight peptides are regarded as a potential source for developing new antibiotics to
solve the drug resistance caused by conventional antibiotics [25]. Dermaseptin-PH demonstrated a
broad-spectrum antimicrobial activity against Gram-negative, Gram-positive bacteria, and yeast.
The antimicrobial mechanism of dermaseptins has been reported to bind to lipid bilayers by
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coil-to-helix transition, and induce the permeation/disruption of the lipid plasma membrane through
the carpet model [18]. It could explain the weaker antimicrobial potency of Dermaseptin-PH
than Dermaseptin S9 as Dermaseptin S9 has a larger proportion of the α-helical domain than
Dermaseptin-PH [26]. Dermaseptin-PH displayed more effective permeabilisation activity on E. coli
than on P. aeruginosa may also owe to the more resistant cellular envelop structure of P. aeruginosa.
Unexpectedly, Dermaseptin-PH exhibited permeation on MRSA though it was not able to inhibit
growth of MRSA in a suitable growing environment. It is speculated that Dermaseptin-PH form the
transmembrane pores rapidly, but this crisis in the membrane might be relieved by some kind of
“self-fixing” strategy or enzymatic degradation of peptides. This special phenomenon might be due to
that incident mutations of MRSA promote the adaption of harsh environment [27]. On the other hand,
the acting pattern of Dermaseptin-PH on MRSA indicated that it may permeabilise cell membranes
through other pore formation models instead of the carpet model. Although Dermaseptin-PH can
interact with cell membranes and cause permeabilisation, its antimicrobial activity was significantly
decreased when encountering more complex bacteria strains and propagation circumstances, such as
biofilm-sessile bacteria. It is widely accepted that high cationic charge may play a more important role
in antimicrobial activity of the most antimicrobial peptides. The published literature revealed that
the most common approach to enhance antimicrobial activity is to introduce basic amino acids in the
amino acids sequence, like lysine. Whereas antimicrobial results of Dermaseptin-PH may illustrate it
exerts antimicrobial functions more dependent on amphipathicity, than positively charged features,
upon interaction with the cell membrane.
Many AMPs display anticancer activity so that they attract much attention of researchers on
anticancer drug discovery [28]. The mechanisms of antimicrobial peptides exhibiting anticancer activity
such as disrupting cell membranes, inhibiting the growth of cancer cells, or killing cancer cells, have not
yet been studied thoroughly. Some literature declared that some AMPs can kill tumour cells specifically.
One reason is that the negatively-charged substances, like heparin sulphates and O-glycosylated
mucins on the surface of cancer cells, could favour the interaction between AMPs and tumour
cells [29–33]. Meanwhile, some scientists deduced that electrostatic force is not the decisive factor of
the interaction between AMPs and cancer cells [34,35]. Although studies showed that some AMPs can
induce cell apoptosis on eukaryote by reactive oxygen species (ROS) production, caspase activation,
cytochrome c release, DNA fragmentation, and mitochondrial membrane depolarisation [36,37],
Dermaseptin B2 was reported to induce the cell necrosis by the membrane disruption of cancer
cells [38]. Here, considering Dermaseptin-PH contains less cationic charges and low degree of α-helicity,
a further study of the permeabilisation of Dermaseptin-PH on cancer cells was carried out through a
time course assay. By observation of rapid membrane permeabilisation activity on cancer cells, it was
speculated that Dermaseptin-PH possesses similar permeation/disruption mechanisms for both cancer
and bacteria cells. Interestingly, the interaction between Dermaseptin-PH and cancer cell membrane
entered a slow growth period, after the initial rapid rise duration. This phenomenon may be explained
by the long-lasting light irradiation from the light source inside the plate reader [39], and the lack of
appropriate growth conditions. It might cause cell cytological instability, which makes cancer cells
more sensitive to Dermaseptin-PH.
In summary, we reported the identification and characterisation of a novel dermaseptin
peptide, named Dermaseptin-PH, from the skin secretion of the South America orange-legged
leaf frog, Pithecopus hypochondrialis. Dermaseptin-PH showed a broad-spectrum of antimicrobial
and anticancer activities. The cell membrane permeability against bacteria and cancer cells
indicated that Dermaseptin-PH stands a good chance of a permeation/disruption dependent peptide.
However, concerning the diverse structures of dermaseptins, the bioactivities may also be relevant
to their structures. Hence, whether functions of dermaseptins have a strong connection with their
structures still need to be investigated intensively. The discovery of AMPs with multiple functions
brought a new possibility for the treatment of human disease. Although there are shortcomings
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for the clinical application of AMPs, there is still a strong confidence for the prospect of their
therapeutic applications.
4. Materials and Methods
4.1. Acquisition of Pithecopus hypochondrialis Skin Secretion
Specimens of the South American orange-legged leaf frog, Pithecopus hypochondrialis were obtained
as captive-bred adults, and were settled into their new surroundings for least three months prior to
experimentation. All specimens were housed separately in purpose designed terraria under 12 h/12 h
light/dark cycles, and were fed multivitamin-loaded crickets three times per week. Skin secretions
were obtained by transdermal electrical stimulation after the method of Tyler et al. and these were
washed from the skin using de-ionised water, snap-frozen in liquid nitrogen, lyophilised, and stored
at 20 ◦C prior to analysis [40]. The study was performed according to the guidelines in the UK
Animal (Scientific Procedures) Act 1986, project license PPL 2694, issued by the Department of Health,
Social Services and Public Safety, Northern Ireland. Procedures had been vetted by the IACUC of
Queen’s University Belfast, and approved on 1 March 2011.
4.2. “Shotgun” Cloning of Dermaseptin-PH Precursor-Encoding cDNA from a Skin Secretion-Derived cDNA
Library of Pithecopus hypochondrialis
Five milligrams of lyophilised skin secretion were dissolved in 1 mL lysis/binding buffer
(Dynal Biotech, Merseyside, UK). Polyadenylated mRNA was isolated by using a magnetized
Dynabeads® mRNA DirectTM Kit (Dynal Biotech, Merseyside, UK) from the decanted supernatant.
Subsequently, the first-strand cDNA was synthesised, and the rapid amplification of cDNA
ends PCR (RACE-PCR) was performed to obtain the full length of prepropeptide nucleic acid
sequence using a SMART-RACE Kit (Clontech, Palo Alto, CA, USA). The nested universal
primer supplied with the kit was used by combination of the degenerate sense primer
(S1; 5′-ACTTTCYGAWTTRYAAGMCCAAABATG-3′) (Y = C/T; W = A/T; R = A/G; M = A/C;
B = T/C/G) that was designed based on the highly conserved signal peptide regions of dermaseptin
peptides published previously from subfamily Phyllomedusinae. Purification of PCR products were
carried out using a ConcertTM Rapid PCR Purification System (Life Technologies, Warrington, UK) and
the products were cloned using a pGEM®-T Easy Vector system (Promega Corporation, Southampton,
UK). And an ABI 3100 automated capillary sequencer (Applied Biosystems, Foster City, CA, USA) was
used to analyse the nucleotide sequence of selected cloned products.
4.3. Identification and Structural Characterization of the Putative Dermaseptin-PH from the Skin Secretion of
Pithecopus hypochondrialis
Five mg of lyophilised skin secretion from Pithecopus hypochondrialis were dissolved in 1 mL
of trifluoracetic acid (TFA)/water (0.05/99.95, v/v) and centrifuged at 5000× g for 20 min to clarify.
The supernatant was injected into an RP-HPLC system (Waters, Miford, MA, USA) fitted with a
column (Jupiter C-5, 5 µM, 4.6 mm × 250 mm, Phenomenex, Macclesfield, Cheshire, UK) and eluted
with a linear gradient mobile phase from TFA/waster (0.05/99.95, v/v) to TFA/water/acetonitrile
(0.05/19.95/80.00, v/v/v) at a flow rate of 1 mL/min in 240 min, detected by the ultraviolet absorbance
at 214 nm. Each fraction was collected automatically at 1 min intervals, and then analysed by a
MALDI-TOF-MS (Voyager DE, Perspective Biosystems, Foster City, CA, USA) in positive detection
mode, using α-cyano-4-hydroxycinnamic acid (CHCA) as the matrix. The system was calibrated by
standards with precision reaching ± 0.1%. Fractions containing identical molecular masses correspond
with the deduced mature peptide from the cloned cDNA were injected into to an LCQ-Fleet electrospray
ion-trap mass spectrometer (Thermo Fisher Scientific, San Francisco, CA, USA) to analysis sequence
structure by MS/MS fragmentation sequencing technique.
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4.4. Solid-Phase Peptide Synthesis
Peptide was chemically-synthesised by solid-phase Fmoc Chemistry using a Tribute® PS4
automated solid-phase peptide synthesizer (Protein Technologies, Tucson, AZ, USA) for bioactive
assessment after the primary structure of the peptide was confirmed. Purity result of the synthesised
peptide was identified by RP-HPLC and MALDI-TOF-MS reaching up to 95%.
4.5. Determination of Dermaseptin-PH Second Structure Using Circular Dichroism Spectroscopy
The secondary structure of Dermaseptin-PH was determined using a JASCO J-815 CD
spectrometer (Jasco, Essex, UK). Chemically-synthesised peptide was dissolved in 10 mM ammonium
acetate and 10 mM ammonium acetate with 50% TFE, respectively, and was prepared at 50 µM in a
1 mm precision quartz cell (Hellma Analytics, Essex, UK). CD spectra were recorded at a wavelength
ranging from 190 nm to 260 nm with a 200 nm/min scan speed. The parameters were set as 1 nm
bandwidth and 0.5 nm data pitch and the results were analysed by the DichroWeb webserver to
estimate α-helical content [17].
4.6. Antimicrobial Assays
Antimicrobial activity of synthetic Dermaseptin-PH was assessed by determination of MIC and
MBC assays using six standard bacteria, including Gram-negative bacteria Escherichia coli (NCTC 10418),
and Pseudomonas aeruginosa (ATCC 27853); Gram-positive bacteria Staphylococcus aureus (NCTC 10788),
methicillin-resistant Staphylococcus aureus (MRSA) (NCTC 12493), and Enterococcus faecalis (NCTC
12697); and pathogenic yeast Candida albicans (NCYC 1467). Each microorganism was inoculated in
Mueller–Hinton broth (MHB) (Sigma-Aldrich, St. Louis, MO, USA) for 16–18 h, and then subcultured
until reaching the logarithmic growth phase, by measuring optical density (OD) of the cultures at
wavelength 550 nm. Then, the cultures were diluted to obtain 1 × 106 colony forming units (cfu)/mL
for the bacteria, and 1 × 105 cfu/mL for the yeast, and incubated with various concentrations
of Dermaseptin-PH, with final concentration range from 1 to 512 µM in a 96 well microtiter cell
culture plate. Plates were incubated for 18 h at 37 ◦C in a humid atmosphere, and the growth of
bacteria/yeast was determined by means of measuring absorbance values at wavelength 550 nm
using a Synergy HT plate reader (Biotech, Minneapolis, MN, USA). The MIC results were defined
as the lowest concentrations of peptide at which no distinct growth of the microorganisms was
detectable. For the MBC assay, the culture in each well was spotted onto a Mueller–Hinton agar (MHA)
(Sigma-Aldrich, St. Louis, MO, USA) plate, and incubated at 37 ◦C in a humid atmosphere for 18 h.
The MBC results were defined as the lowest concentrations of peptide at which no obvious colony
was observed.
4.7. Minimum Biofilm Inhibitory Concentration (MBIC) and Minimum Biofilm Eradication Concentration
(MBEC) Assays
Gram-negative bacterium Escherichia coli (NCTC 10418) was inoculated in Luria–Bertani (LB) broth
(Sigma-Aldrich, St. Louis, MO, USA); Gram-positive bacteria Staphylococcus aureus (NCTC 10788) was
inoculated in tryptic soy broth (TSB) (Sigma-Aldrich, St. Louis, MO, USA) for 16–18 h, and then
subcultured until reaching the logarithmic growth phase by measuring OD of the cultures at
wavelength 550 nm. For the MBIC assay, the cultures were diluted to obtain 1 × 106 cfu/mL,
and incubated with various concentrations of Dermaseptin-PH with final concentration range from
1 to 512 µM in a 96 well flat-bottomed microtiter cell culture plate for 16 to 20 h at 37 ◦C in a shaking
incubator at different revolutions per minute (rpm), according to different bacteria. After, plates
were washed twice by phosphate buffered saline (PBS) and fixed with methanol for 10 min. For the
MBEC assay, 100 µL of the cultures were placed in a 96 well flat-bottomed microtiter cell culture
plate with a diluted colony concentration of 1 × 106 cfu/mL, and incubated at 37 ◦C for 16–20 h in
a shaking incubator at different rpm, on the basis of different bacteria. After, plates were washed
Molecules 2017, 22, 1805 15 of 18
twice by PBS and incubated with 100 µL of Dermaseptin-PH dissolved in relevant culture medium,
in a range of concentrations from 1 to 512 µM. Sixteen to twenty hours after exposure, plates were
washed twice by PBS, and fixed with methanol for 10 min. Both MBIC and MBEC plates were stained
with 150 µL 0.1% (g/v) crystal violet solutions for 30 min, and washed by PBS until no apparent
stains were observed. Evaporating crystal violet stains were dissolved by 100 µL 30% (v/v) acetic
acid, and the absorbance values were measured at wavelength 595 nm using a Synergy HT plate
reader (Biotech, Minneapolis, MN, USA). The minimum concentration that inhibits the formation of
biofilm is defined when compared to the negative control group as MBIC i.e., ≥90% (for MBIC90)
and MBIC i.e., ≥50% (for MBIC50). The minimum concentration that eradicates the biofilm is defined
when compared to the negative control group as MBEC i.e., ≥90% (for MBEC90) and MBEC i.e., ≥50%
(for MBEC50) [41].
4.8. Bacteria Cell Membrane Permeability Assay of Dermaseptin-PH
Bacteria were inoculated in TSB (Sigma-Aldrich, St. Louis, MO, USA) at 37 ◦C for 16 to 18 h,
and then subcultured until reaching the logarithmic growth phase, by measuring OD of the cultures at
wavelength 550 nm. Then, bacterial cells were collected, centrifuged at 1000× g for 10 min at 4 ◦C,
where after, cells were washed twice with 5% TSB in 0.85% NaCl solution. The pellet was resuspended
with 5% TSB in 0.85% NaCl solution to obtain a cell concentration of 1 × 108 cfu/mL by measuring
optical density (OD) at wavelength 590 nm. The cells were incubated with Dermaseptin-PH in a range
of concentrations based on the MIC results in a 96 well black plate at 37 ◦C. Two hours after exposure,
the cells were stained with SYTOXTM green nucleic acid stain (Life technologies) dissolved in 5% TSB in
0.85% NaCl to a final concentration of 5 µM, and incubated for 5min in the dark at 37 ◦C. The fluorescent
intensity was measured with a Synergy HT plate reader (Biotech, Minneapolis, MN, USA) by an
excitation and emission wavelength of 485 and 528 nm, respectively. Bacteria cells treated with
70% (v/v) isopropanol for 1 h were used as positive control.
4.9. Haemolysis Assay
The defibrinated horse blood (TCS Biosciences Ltd., Botolph Clayton, UK) was collected,
centrifuged at 1000× g for 5 min, where after, cells were washed with PBS until the supernatant
was clean. The cells were resuspended with PBS to obtain a cell concentration of 4% (v/v). The pellet
was incubated with Dermaseptin-PH in a range of final concentration from 1 to 512 µM at 37 ◦C.
Two hours after exposure, supernatant was collected, centrifuged at 1000× g for 5 min, and placed
into a 96 well plate. The absorbance was measured at wavelength 570 nm using a Synergy HT plate
reader (Biotech, Minneapolis, MN, USA). Cells treated with 1% (v/v) Triton-X 100 for 2 h were used as
positive control.
4.10. MTT Cell Proliferation Assay
MCF-7 (ATCC-HTB-22), MDA-MB-435S (ATCC-HTB-129), and U251MG (ECACC-09063001)
were cultured in DMEM (Invitrogen, Paisley, UK) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA) and 1% (v/v) penicillin–streptomycin
(Invitrogen, Paisley, UK). PC-3 (ATCC-CRL-1435) and H157 (ATCC-CRL-5802) were cultured
in RPMI-1640 (Invitrogen, Paisley, UK) supplemented with 10% (v/v) FBS and 1% (v/v)
penicillin–streptomycin. HMEC-1 (ATCC-CRL-3243) was cultured in MCDB131 (Gibco, Paisley,
UK) supplemented with 10% (v/v) FBS, 1% (v/v) penicillin–streptomycin, 10 ng/mL epidermal
growth factor (EGF), 10 mM L-glutamine, and 1 µg/mL hydrocortisone. Cells were grown in a
96 well plate (5000 cells/well/100 µL) for 24 h, and treated with relevant serum-free medium for 12 h.
After, cells were treated with Dermaseptin-PH dissolved in relevant serum-free medium in a range
of concentrations, from 10−9 to 10−4 M. Twenty-four hours after exposure, the cells were incubated
with MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphehyltetrazolium Bromide) dissolved in PBS to a final
concentration of 0.5 mg/mL at 37 ◦C for 4 to 6 h. After, medium in each well was removed and 100 µL
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dimethyl sulfoxide (DMSO) was added. Cell viability was measured at wavelength 570 nm using a
Synergy HT plate reader (Biotech, Minneapolis, MN, USA).
4.11. Cancer Cell Membrane Permeability Assay of Dermaseptin-PH
The permeability of Dermaseptin-PH on MCF-7 cell was determined using SYTOXTM green
nucleic acid stain (Life technologies). MCF-7 cells were grown in a sterile black 96 well plate
(5000 cells/well/100 µL) for 24 h, and treated with relevant serum-free medium for 12 h. After, cells
were incubated with SYTOXTM green stain (1 µM) for 15 min and subsequently were treated
with various concentrations of Dermaseptin-PH with final concentrations range from 10−6 to
10−4 M. The fluorescence was measured every 15 min for 75min with a Synergy HT plate reader
(Biotech, Minneapolis, MN, USA) by an excitation and emission wavelength of 485 and 528 nm,
respectively. Cells treated with 0.5% Triton X-100 were used as positive control.
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